E
72.95
-0.99 (-1.34%)
| Previous Close | 73.94 |
| Open | 73.17 |
| Volume | 3,937,506 |
| Avg. Volume (3M) | 4,500,135 |
| Market Cap | 42,828,947,456 |
| Price / Earnings (TTM) | 30.52 |
| Price / Earnings (Forward) | 27.86 |
| Price / Sales | 7.97 |
| Price / Book | 4.27 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
2.6
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 2.63 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 88.00 (Wells Fargo, 20.63%) | Buy |
| 88.00 (Evercore ISI Group, 20.63%) | Buy | |
| Median | 88.00 (20.63%) | |
| Low | 85.00 (Stifel, 16.52%) | Buy |
| Average | 87.00 (19.26%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 76.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 88.00 (20.63%) | Buy | 76.72 |
| Stifel | 22 Sep 2025 | 85.00 (16.52%) | Buy | 73.75 |
| Wells Fargo | 07 Aug 2025 | 88.00 (20.63%) | Buy | 77.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Oct 2025 | Announcement | Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025 |
| 27 Oct 2025 | Announcement | Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 |
| 23 Oct 2025 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 |
| 29 Aug 2025 | Announcement | Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care |
| 19 Aug 2025 | Announcement | Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase |
| 06 Aug 2025 | Announcement | Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |